BIG Breast International Group
We will find a cure for breast cancer through global research and collaboration.

BIG 1-06 Neo-ALTTO

The Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment Organisation (Neo-ALTTO) study is a randomised, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer.

Coordinating groups: BrEAST / SOLTI

Patients accrual
Start date: December 2007
Closure date: December 2009
Target nr. of patients: 450
Final accrual: 454

Reason for closure: reached target accrual
ClinicalTrials.gov Identifier: NCT00553358

To learn more, visit: http://alttotrials.com/neoaltto.php

Scroll to top

Contact us

Breast International Group (BIG)-aisbl Blvd de Waterloo 121 B-1000 Brussels | Belgium VAT BE 0468 176 240